(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

On September 20, 2012, the BioMimetic Board held a telephonic meeting attended by each member of the BioMimetic Board and representatives of Ropes & Gray and Goldman Sachs. Dr. Lynch described his most recent interactions with Wright and summarized the terms proposed by Wright. A representative from Goldman Sachs followed with a presentation of its financial analysis of those terms. The BioMimetic Board discussed the financial analysis and determined it was satisfied with the consideration proposed by Wright and did not believe Wright would be willing to pay more. The BioMimetic Board then discussed whether to conduct a pre-signing market

check and concluded that Goldman Sachs should contact third parties on behalf of BioMimetic. With input from BioMimetic’s management and Goldman Sachs, the BioMimetic Board assessed which companies would be most likely to have an interest in acquiring BioMimetic based on their financial capacity and strategic focus on BioMimetic’s business area. The BioMimetic Board’s views were further informed by past discussions with various parties regarding potential business combinations, including with Wright, as well as directors’ knowledge of the industry and particular companies. As a result of such past conversations, the BioMimetic Board had obtained information about whether certain parties may be interested in acquiring BioMimetic and whether such parties may remain interested in acquiring BioMimetic before it received U.S. Food and Drug Administration (“FDA”) approval of Augment^® Bone Graft. The BioMimetic Board determined to focus the pre-market check on a select group of 15 strategic counter-parties, which the BioMimetic Board believed had sufficient financial capacity to complete an acquisition of BioMimetic, shared a strategic focus on BioMimetic’s business area and may be interested in acquiring BioMimetic, in order to concentrate resources on the most likely acquirors. The BioMimetic Board, in consultation with Goldman Sachs, determined not to contact private equity firms because they were not likely to be interested in acquiring BioMimetic, in part because it was anticipated that BioMimetic would experience operating losses through 2015, as shown in the forecasts set forth on page 69 of the Proxy Statement. After considerable discussion, it was the unanimous view of the BioMimetic Board that, while BioMimetic was not currently for sale, management and BioMimetic’s advisors should simultaneously (1) engage with Wright, by providing diligence materials, conducting reverse due diligence, and discussing possible non-price terms for a potential business combination; and (2) contact potential other counter-parties to explore their interest in a possible business combination transaction.

On October 19, 2012, the BioMimetic Board held a telephonic meeting attended by a quorum of the BioMimetic Board and representatives of Ropes & Gray and Goldman Sachs. Dr. Lynch began with a summary of recent diligence activities between BioMimetic and Wright, including the regulatory diligence sessions held on October 16, 2012, with outside counsel, and summarized his negotiation with Mr. Davis following the regulatory diligence session. The BioMimetic Board discussed Dr. Lynch’s summary and authorized Dr. Lynch to proceed with the negotiations with Wright under the terms discussed by the BioMimetic Board. Dr. Lynch also noted that the parties had exchanged drafts of the proposed merger agreement and contingent value rights agreement. He then reviewed the tentative timeline for a transaction. A representative of Goldman Sachs also updated the BioMimetic Board on the market check activities and noted that Bidder B did not appear to be actively engaged and was unlikely to pursue the opportunity. The Goldman Sachs representative stated that representatives of Bidder B had not accessed the electronic data room containing BioMimetic’s diligence materials and had not returned phone calls inquiring about Bidder B’s interest in BioMimetic.

Also on October 26, 2012, Wright and BioMimetic’s management, along with Larry Papasan and Charles Federico, members of the BioMimetic Board, and representatives of Goldman Sachs held a diligence session in Arlington, Tennessee to cover financial and tax matters related to both companies and the general business and

growth prospects for Wright. Additionally, at the conclusion of the diligence session on October 26, 2012, Mr. Palmisano met with Dr. Lynch and Messrs. Papasan and Federico to discuss Dr. Lynch’s role after closing the potential transaction. Dr. Lynch had recently expressed to Mr. Davis his preference not to continue with the combined company after closing, but Mr. Palmisano stated that it was important to Wright that Dr. Lynch remain an employee of the combined company during a transition period following the closing date. During its telephonic meeting on October 19, 2012, the BioMimetic Board discussed the upcoming diligence session on October 26, 2012, between Wright and BioMimetic’s management. The October 26, 2012 diligence session included the participation of Messrs. Papasan and Federico. During the October 19, 2012 telephonic meeting, however, the BioMimetic Board did not discuss whether at the October 26, 2012 diligence session Dr. Lynch and Messrs. Papasan and Federico would discuss Dr. Lynch’s role at BioMimetic after closing the potential transaction with Mr. Palmisano. Such a discussion had not been anticipated to take place at the October 26, 2012 diligence session.

The non-public internal financial analyses for BioMimetic prepared by its management included in the Proxy Statement assumed a 90% probability of receiving FDA approval of Augment^® Bone Graft and Augment^® Injectable Bone Graft and a 60% probability of receiving FDA approval of Augment^® Chronic Tendinopathy.

The following is a summary of certain of the forecasts prepared by management of BioMimetic and provided to the BioMimetic Board and Goldman Sachs (numbers in millions)

Year

Taxes payable

Share count

The following is a summary of certain of the cash flow forecasts of BioMimetic prepared by management of BioMimetic and provided to the BioMimetic Board and Goldman Sachs (numbers in millions)¹

Year

Net cash provided by operating activities

Purchases of property and equipment

Capitalized patent license fees

Unlevered free cash flow

Assumes (i) the FDA’s approval of Augment^® Bone Graft on March 31, 2013 with a launch date on July 31, 2013, (ii) the probability-adjusted revenue of 90% Augment^® Bone Graft and Augment^® Injectable Bone Graft and (iii) revenue from sports medicine products beginning 2018 (with a 60% probability of success for Tendinosis).

BioMimetic’s management also provided the BioMimetic Board and Goldman Sachs with BioMimetic management’s assessments as to the probability and estimated timing of achievement of the approval milestone and the product sales milestones with respect to the CVRs, referred to as the CVR projections. The CVR projections were based on the experience and professional judgment of BioMimetic’s management after considering, among other matters specific to BioMimetic’s business, industry performance, general business, economic, regulatory, market and financial conditions and other future events of BioMimetic.